Surface expression of CD192 is down-modulated even in the remission phase in MS, and down-modulation is rather enhanced by IFN-β therapy probably being one of the self-protective mechanisms against MS partly contributing to sustained remission by preventing monocyte infiltration into the CNS [53]. Here, CCR2 is linked to myeloid sarcoma.